C07K 16/2833
Against mhc-molecules
Official title: {against MHC-molecules, e.g. HLA-molecules}
C07K16/2833 (Against mhc-molecules) appears on 951 US grants and 1,757 published applications in this corpus.
Search patents in C07K- Granted patents
- 951
- Published applications
- 1,757
- Assignees
- 437
- Inventors
- 2,021
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 4 | 0 |
| 1999 | 10 | 0 |
| 2000 | 8 | 0 |
| 2001 | 13 | 8 |
| 2002 | 7 | 19 |
| 2003 | 4 | 30 |
| 2004 | 7 | 10 |
| 2005 | 8 | 21 |
| 2006 | 3 | 23 |
| 2007 | 6 | 15 |
| 2008 | 5 | 14 |
| 2009 | 11 | 28 |
| 2010 | 10 | 33 |
| 2011 | 18 | 34 |
| 2012 | 14 | 32 |
| 2013 | 24 | 44 |
| 2014 | 26 | 66 |
| 2015 | 26 | 55 |
| 2016 | 40 | 79 |
| 2017 | 39 | 92 |
| 2018 | 68 | 109 |
| 2019 | 99 | 144 |
| 2020 | 91 | 132 |
| 2021 | 75 | 143 |
| 2022 | 93 | 194 |
| 2023 | 56 | 122 |
| 2024 | 84 | 150 |
| 2025 | 62 | 100 |
| 2026 | 26 | 60 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- MICA/B antibodies and methods of use29 Sep 2026US 12,747,293 B2Cullinan Mica Corporation
- Multi-domain CD1a antagonist/PD-1 agonist antibody molecules15 Sep 2026US 12,735,491 B2Immunocore Limited
- Antigen binding molecules and methods thereof II1 Sep 2026US 12,723,088 B2Agency for Science, Technology and Research
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Anti-MICA/B antibodies that block MICA/B shedding and methods of use14 Jul 2026US 12,679,894 B2Cullinan Mica Corporation
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- High-affinity t cell receptor for identifying kras mutation and use thereof1 Oct 2026US 2026/0297159 A1Xlifesc, Ltd.
- Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide24 Sep 2026US 2026/0284218 A1Cdr-Life AG
- Tcr with high affinity and specificity specific for preproinsulin peptide alwgpdpaaa bound to hla-a2*0224 Sep 2026US 2026/0285984 A1
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005